In the United States,<unk>  is indicated for the treatment of adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease; and with moderately to severely active ulcerative colitis. In the European Union and in Australia,<unk>  is indicated for the treatment of adults with relapsing remitting multiple sclerosis.
Ozanimod
Siponimod
Ponesimod
Belinostat
Nusinersen
Inotersen
Calaspargase pegol
Aflibercept